CD40 and metastatic neoplasm: Among those who never received immunotherapy, the median OS from advanced/metastatic disease was 63.3 months (95% CI, 33.7–Not available [NA]) in the high-CD40 group and 42.2 months (95% CI, 30.1–46.2) in the low-CD40 group (P = 0.16; Fig. 7A).